Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience.
RECIST
chemoembolization
intra-arterial therapies
liver metastases
mRECIST
neuroendocrine neoplasms
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Oct 2021
26 Oct 2021
Historique:
received:
11
09
2021
revised:
15
10
2021
accepted:
15
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
transarterial chemoembolization (TACE) is an established treatment for neuroendocrine tumor (NET) liver metastases. The aim was to evaluate the long-term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival. this IRB-approved, single-center, retrospective study evaluated all TACE procedures performed for NET liver metastases from 2003-2017 for imaging tumor response (RECIST and mRECIST), time to liver progression (TT 555 TACE procedures were performed in 202 NET patients (38% grade 1, 60% grade 2) with primary tumors originating from pancreas, small bowel, and lung (39, 26, and 22% respectively). Median follow-up was 8.2 years (90-139 months). Median TT TACE for NET liver metastases provides objective response and sustained local disease control rates. RECIST and mRECIST responses correlate with OS.
Sections du résumé
BACKGROUND
BACKGROUND
transarterial chemoembolization (TACE) is an established treatment for neuroendocrine tumor (NET) liver metastases. The aim was to evaluate the long-term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival.
METHODS
METHODS
this IRB-approved, single-center, retrospective study evaluated all TACE procedures performed for NET liver metastases from 2003-2017 for imaging tumor response (RECIST and mRECIST), time to liver progression (TT
RESULTS
RESULTS
555 TACE procedures were performed in 202 NET patients (38% grade 1, 60% grade 2) with primary tumors originating from pancreas, small bowel, and lung (39, 26, and 22% respectively). Median follow-up was 8.2 years (90-139 months). Median TT
CONCLUSION
CONCLUSIONS
TACE for NET liver metastases provides objective response and sustained local disease control rates. RECIST and mRECIST responses correlate with OS.
Identifiants
pubmed: 34771531
pii: cancers13215366
doi: 10.3390/cancers13215366
pmc: PMC8582443
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Dig Liver Dis. 2020 May;52(5):473-492
pubmed: 32234416
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
J Vasc Interv Radiol. 2014 Jan;25(1):22-30; quiz 31
pubmed: 24365504
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Vasc Interv Radiol. 2013 Jul;24(7):947-56; quiz 957
pubmed: 23602421
Neuroendocrinology. 2017;105(1):26-34
pubmed: 27225439
Semin Intervent Radiol. 2013 Mar;30(1):28-38
pubmed: 24436515
Cardiovasc Intervent Radiol. 2012 Oct;35(5):980-5
pubmed: 22009576
Oncology. 2017;92(6):353-359
pubmed: 28329738
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Ann Surg Oncol. 2016 Nov;23(12):4008-4015
pubmed: 27393568
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Int J Cancer. 2016 Dec 15;139(12):2679-2686
pubmed: 27553864
Cardiovasc Intervent Radiol. 2008 Mar-Apr;31(2):299-307
pubmed: 17922160
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
J Gastrointest Surg. 2007 Dec;11(12):1680-5
pubmed: 17899303
Cancer. 2005 Oct 15;104(8):1590-602
pubmed: 16134179
Radiology. 2013 Feb;266(2):502-13
pubmed: 23192780
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
Cardiovasc Intervent Radiol. 2013 Apr;36(2):449-59
pubmed: 22722717
Ann Surg Oncol. 2017 Feb;24(2):450-459
pubmed: 27663565
Target Oncol. 2012 Jun;7(2):107-16
pubmed: 22707276
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Hepatol. 2012 Mar;56(3):609-17
pubmed: 22027582
Endocr Relat Cancer. 2010 Oct 05;17(4):909-18
pubmed: 20702725
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
AJR Am J Roentgenol. 2008 Jan;190(1):67-73
pubmed: 18094295
J Vasc Interv Radiol. 1999 Apr;10(4):397-403
pubmed: 10229465
Pancreas. 2020 Aug;49(7):863-881
pubmed: 32675783
Hepatogastroenterology. 2004 Nov-Dec;51(60):1751-6
pubmed: 15532819
Cardiovasc Intervent Radiol. 2016 Mar;39(3):334-43
pubmed: 26390875
Ann Surg Oncol. 2011 Dec;18(13):3657-65
pubmed: 21681380
Cardiovasc Intervent Radiol. 2017 Jan;40(1):69-80
pubmed: 27738818
Radiology. 2017 Jun;283(3):883-894
pubmed: 27831830